Jankowitz, RC and Cooper, K and Erlander, MG and Ma, XJ and Kesty, NC and Li, H and Chivukula, M and Brufsky, A
(2011)
Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.
Breast Cancer Research, 13 (5).
ISSN 1465-5411
Abstract
Introduction: Breast Cancer Index (BCI) combines two independent biomarkers, HOXB13:IL17BR (H:I) and the 5-gene molecular grade index (MGI), that assess estrogen-mediated signalling and tumor grade, respectively. BCI stratifies early-stage estrogen-receptor positive (ER+), lymph-node negative (LN-) breast cancer patients into three risk groups and provides a continuous assessment of individual risk of distant recurrence. Objectives of the current study were to validate BCI in a clinical case series and to compare the prognostic utility of BCI and Adjuvant!Online (AO). Methods: Tumor samples from 265 ER+LN- tamoxifen-treated patients were identified from a single academic institution's cancer research registry. The BCI assay was performed and scores were assigned based on a pre-determined risk model. Risk was assessed by BCI and AO and correlated to clinical outcomes in the patient cohort. Results: BCI was a significant predictor of outcome in a cohort of 265 ER+LN- patients (median age: 56-y; median follow-up: 10.3-y), treated with adjuvant tamoxifen alone or tamoxifen with chemotherapy (32%). BCI categorized 55%, 21%, and 24% of patients as low, intermediate and high-risk, respectively. The 10-year rates of distant recurrence were 6.6%, 12.1% and 31.9% and of breast cancer-specific mortality were 3.8%, 3.6% and 22.1% in low, intermediate, and high-risk groups, respectively. In a multivariate analysis including clinicopathological factors, BCI was a significant predictor of distant recurrence (HR for 5-unit increase = 5.32 [CI 2.18-13.01; P = 0.0002]) and breast cancer-specific mortality (HR for a 5-unit increase = 9.60 [CI 3.20-28.80; P < 0.0001]). AO was significantly associated with risk of recurrence. In a separate multivariate analysis, both BCI and AO were significantly predictive of outcome. In a time-dependent (10-y) ROC curve accuracy analysis of recurrence risk, the addition of BCI+AO increased predictive accuracy in all patients from 66% (AO only) to 76% (AO+BCI) and in tamoxifen-only treated patients from 65% to 81%. Conclusions: This study validates the prognostic performance of BCI in ER+LN- patients. In this characteristically low-risk cohort, BCI classified high versus low-risk groups with ~5-fold difference in 10-year risk of distant recurrence and breast cancer-specific death. BCI and AO are independent predictors with BCI having additive utility beyond standard of care parameters that are encompassed in AO.
Share
| Citation/Export: |
|
| Social Networking: |
|
Details
| Item Type: |
Article
|
| Status: |
Published |
| Creators/Authors: |
| Creators | Email | Pitt Username | ORCID  |
|---|
| Jankowitz, RC | rcj8@pitt.edu | RCJ8 | | | Cooper, K | | | | | Erlander, MG | | | | | Ma, XJ | | | | | Kesty, NC | | | | | Li, H | | | | | Chivukula, M | | | | | Brufsky, A | adb5@pitt.edu | ADB5 | |
|
| Centers: |
Other Centers, Institutes, Offices, or Units > Pittsburgh Cancer Institute |
| Date: |
14 October 2011 |
| Date Type: |
Publication |
| Journal or Publication Title: |
Breast Cancer Research |
| Volume: |
13 |
| Number: |
5 |
| DOI or Unique Handle: |
10.1186/bcr3038 |
| Schools and Programs: |
School of Public Health > Biostatistics
School of Medicine > Medicine
School of Medicine > Pathology |
| Refereed: |
Yes |
| ISSN: |
1465-5411 |
| Date Deposited: |
26 Oct 2016 17:11 |
| Last Modified: |
30 Mar 2021 17:55 |
| URI: |
http://d-scholarship.pitt.edu/id/eprint/30011 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Altmetric.com
Actions (login required)
 |
View Item |
![[img]](http://d-scholarship.pitt.edu/style/images/fileicons/text_plain.png)
![[feed]](/images/feed-icon-32x32.png){kind=icon}